FierceBiotech

Third Harmonic’s song to end as biotech looks to liquidate, sell off urticaria drug

Third Harmonic Bio has abandoned plans to take its chronic spontaneous urticaria (CSU) drug into phase 2, instead preparing to sell the asset while liquidating the business. The writing was on the ...
FierceBiotech

Third Harmonic halves headcount to take urticaria drug into phase 2 despite side effects

Third Harmonic Bio will lay off half of its workforce, the biotech has said as it prepares to take its chronic spontaneous urticaria (CSU) candidate into phase 2. The company announced results for a ...